Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 56,000 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 56,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total value of $6,475,280.00. Following the sale, the chief executive officer now owns 74,087 shares in the company, valued at $8,566,679.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

TransMedics Group Price Performance

Shares of TMDX stock opened at $127.99 on Friday. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $129.66. The stock has a fifty day simple moving average of $85.54 and a two-hundred day simple moving average of $76.85. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The firm had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. During the same period in the prior year, the business posted ($0.08) EPS. The firm’s quarterly revenue was up 132.9% on a year-over-year basis. On average, analysts predict that TransMedics Group, Inc. will post 0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. FMR LLC grew its holdings in TransMedics Group by 42.5% in the third quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after purchasing an additional 1,407,171 shares during the last quarter. Vanguard Group Inc. increased its position in TransMedics Group by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock valued at $147,214,000 after buying an additional 50,673 shares in the last quarter. Eventide Asset Management LLC raised its stake in TransMedics Group by 7.4% in the fourth quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock valued at $78,475,000 after buying an additional 68,884 shares during the last quarter. Sandhill Capital Partners LLC raised its stake in TransMedics Group by 4.2% in the fourth quarter. Sandhill Capital Partners LLC now owns 763,201 shares of the company’s stock valued at $60,239,000 after buying an additional 30,591 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in TransMedics Group by 91.4% in the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock worth $41,615,000 after acquiring an additional 363,012 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Canaccord Genuity Group boosted their target price on TransMedics Group from $102.00 to $117.00 and gave the company a “buy” rating in a research report on Wednesday. Morgan Stanley increased their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. lifted their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an “overweight” rating in a research note on Wednesday. Piper Sandler reissued an “overweight” rating and issued a $120.00 price objective (up from $95.00) on shares of TransMedics Group in a research report on Wednesday. Finally, Oppenheimer raised their price objective on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and a consensus target price of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.